secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001828185-25-000071
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog
----------------------------------------------------------------

- Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.
- Cash and equivalents $75.7M as of Sept 30, down $12.1M from June 30; runway into 2027.
- Announced all-stock merger with Clywedog; combined company renamed Clywedog Therapeutics Holdings, ticker CLYD, close expected H1 2026.
- VTP-1000 celiac SAD data expected by end 2025; MAD data in H2 2026.
- Impairment of $4.7M due to deal valuation; R&D expenses fell to $5.4M from $8.0M QoQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000071/0001828185-25-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000071/brns-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001828185-25-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer